Cynamon M H, Gimi R, Gyenes F, Sharpe C A, Bergmann K E, Han H J, Gregor L B, Rapolu R, Luciano G, Welch J T
Veterans Affairs Medical Center, Syracuse, New York 13210, USA.
J Med Chem. 1995 Sep 29;38(20):3902-7. doi: 10.1021/jm00020a003.
A series of substituted pyrazinoic acid esters has been prepared and examined for their in vitro activity against Mycobacterium avium and Mycobacterium kansasii as well as Mycobacterium tuberculosis. Modification of both the pyrazine nucleus and the ester functionality have been very successful in expanding the activity of pyrazinamide to include M. avium and M. kansasii, organisms normally not susceptible to pyrazinamide. Several of these compounds have activities 100-1000-fold greater than that of pyrazinamide against M. tuberculosis.
已制备了一系列取代的吡嗪酸酯,并对其针对鸟分枝杆菌、堪萨斯分枝杆菌以及结核分枝杆菌的体外活性进行了研究。吡嗪核和酯官能团的修饰在扩大吡嗪酰胺的活性范围以包括鸟分枝杆菌和堪萨斯分枝杆菌方面非常成功,这些微生物通常对吡嗪酰胺不敏感。其中几种化合物对结核分枝杆菌的活性比吡嗪酰胺高100 - 1000倍。